Ishizawa Kenichi | 国立がんセンター東病院

スポンサーリンク

概要

関連著者

もっと見る

著作論文

Extreme eosinophilia caused by interleukin-5-producing disseminated colon cancer
Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
Phase I Study of Intravenous PSC-833 and Doxorubicin: Reversal of Multidrug Resistance
Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis
Acquired hemophilia A with sigmoid colon cancer : successful treatment with rituximab followed by sigmoidectomy
A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma : β2-microglobulin associated with time to progression
Dose Modification of Imatinib by Monitoring the Level of BCR-ABL Transcript in Chronic Myelogenous Leukemia
Increased Expression of Insulin-Like Growth Factor I is Associated with Ara-C Resistance in Leukemia
Imatinib Mesylate in Conjunction with Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Philadelphia Chromosome Positive Leukemias : Report of 4 Cases
Detection of Clone-Specific Immunoglobulin Heavy Chain Genes in the Bone Marrow of B-cell-Lineage Lymphoma after Treatment
High Expression of YB-1 Gene in Erythroid Cells in Patients with Refractory Anemia
Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (^Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma
Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia
Japanese phase II study of ^Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
Case-control study of leukemia and diagnostic radiation exposure
Phase III Study of Ranimustine, Cyclophosphamide, Vincristine, Melphalan, and Prednisolone (MCNU-COP/MP) versus Modified COP/MP in Multiple Myeloma : A Japan Clinical Oncology Group Study, JCOG 9301
Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma
Phenotypic analysis of peripheral T/NK cell lymphoma : Study of 408 Japanese cases with special reference to their anatomical sites
Morphological spectrum of cyclin D1-positive mantle cell lymphoma : Study of 168 cases
Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice
Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients
Extragonadal germ cell tumors in Japan
Treatable Subsets in Cancer of Unknown Primary Origin
Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
Recurrent Breast Cancer Treated Successfully with Mitomycin-C and Vinblastine after Failure of Both Doxorubicin-containing Regimen and Paclitaxel : A Case Report
A Limited Sampling Model for Estimating Pharmacokinetics of CPT-11 and Its Metabolite SN-38
Pharmacological Correlation between Total Drug Concentration and Lactones of CPT-11 and SN-38 in Patients Treated with CPT-11
Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study
Fludarabine- and Cyclophosphamide-Based Nonmyelobalative Conditioning Regimen for Transplantation of Chronic Granulomatous Disease : Possible Correlation with Prolonged Pure Red Cell Aplasia
Photo-Induced Reactions of Oxime O-Ethers Derived from 3-Acyl-1, 2-dihydrocinnoline- 1, 2-dicarboximides
Novel Photo-Rearrangement of Oxime Methyl Ethers of 3-Acyl-1, 2dihydrocinnoline-N-phenyl-1, 2-dicarboximides
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab
Correlation Between Histological Evaluation and PCR-based Clonality Analysis of Gastric MALT Lymphomas Treated by Eradication of Helicobacter pylori
Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma : Japan Clinical Oncology Group study (JCOG 9305)
Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma : 7-year follow-up results
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine : a multicenter study
Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia : a retrospective safety analysis
Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab : A multicenter phase II study

もっと見る

スポンサーリンク